Literature DB >> 9851504

Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers.

E C Gabalski1, M Adam, H Pinto, J M Brown, D A Bloch, D J Terris.   

Abstract

OBJECTIVE: Considerable evidence exists to suggest that tumor hypoxia results in radioresistance. Historically, it has been difficult to assess tumor oxygen tension levels reliably. These levels can now be assessed in head and neck malignancies using the Eppendorf pO2 histograph, which uses a fine-needle electrode and a computerized micromanipulator. This technology was used to compare the pretreatment tumor oxygen tension level in lymph node metastases of patients with head and neck cancer to measurements taken during nonsurgical treatment after a partial response had been achieved. STUDY
DESIGN: Prospective study.
METHODS: Oxygen tension levels were measured in the cervical lymph nodes of 10 patients with biopsy-proven head and neck squamous cell carcinoma and cervical metastases who were being treated with nonsurgical management. These levels were obtained using the Eppendorf pO2 histograph system. Measurements were taken before the start of treatment and were repeated when the size of the cervical metastatic node had decreased by 50%. Normal subcutaneous tissue was measured during the same session. The mean and median pO2 levels, as well as the percentage of measurements with pO2 less than 5 mm Hg were determined.
RESULTS: A mean of 72.6 measurements per session was taken from each lymph node. The median tumor pO2 measurement fell from a mean (+/-SD) of 13.9+/-8.0 mm Hg to 7.3+/-9.9 mm Hg. Even more dramatic, however, was the substantial increase in the percentage of values less than 5 mm Hg, a rise from 29% to 52%.
CONCLUSIONS: While there is variability both in the pretreatment oxygenation of head and neck cervical metastases and in the change in tumor oxygen tension during treatment, there appears to be a decrease in the overall oxygenation of the tumors. The dramatic increase in very low oxygen measurements may reflect selective survival of radioresistant or chemoresistant hypoxic tumor cells. Cells at the very low level would be expected to be radiobiologically hypoxic (resistant to radiation-induced cell kill).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851504     DOI: 10.1097/00005537-199812000-00017

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells.

Authors:  S Kumar; S L Brown; A Kolozsvary; S O Freytag; J H Kim
Journal:  J Neurooncol       Date:  2008-07-02       Impact factor: 4.130

Review 2.  Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.

Authors:  Giacomo Miserocchi; Chiara Spadazzi; Sebastiano Calpona; Francesco De Rosa; Alice Usai; Alessandro De Vita; Chiara Liverani; Claudia Cocchi; Silvia Vanni; Chiara Calabrese; Massimo Bassi; Giovanni De Luca; Giuseppe Meccariello; Toni Ibrahim; Marco Schiavone; Laura Mercatali
Journal:  J Pers Med       Date:  2022-05-24

3.  Hypoxia in head and neck squamous cell carcinoma.

Authors:  John Zenghong Li; Wei Gao; Jimmy Yu-Wai Chan; Wai-Kuen Ho; Thian-Sze Wong
Journal:  ISRN Otolaryngol       Date:  2012-10-16

4.  The HYP-RT hypoxic tumour radiotherapy algorithm and accelerated repopulation dose per fraction study.

Authors:  W M Harriss-Phillips; E Bezak; E Yeoh
Journal:  Comput Math Methods Med       Date:  2012-06-19       Impact factor: 2.238

5.  The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.

Authors:  Carolien Boeckx; Jolien Van den Bossche; Ines De Pauw; Marc Peeters; Filip Lardon; Marc Baay; An Wouters
Journal:  BMC Res Notes       Date:  2015-06-02

6.  Oxygen Imaging for Non-Invasive Metastasis Detection.

Authors:  Joshua Punnoose; Henry Nachman; Shai Ashkenazi
Journal:  Sensors (Basel)       Date:  2021-12-29       Impact factor: 3.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.